Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMP versus VMP in transplant-ineligible newly diagnosed multiple myeloma
NL-OMON44957Phase 3Recruiting
- Sponsor
- Amgen
- Start
- Jun 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of carfilzomib, bortezomib, melphalan and prednisone in multiple myeloma (MM) (2 arms), sponsored by Amgen. Primary endpoint: Progression-free survival. Started Jun 2014; status: recruiting.
02
Drugs
carfilzomibbortezomibmelphalanprednisone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON44957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44957.